CP Reports
CP Insight
Current Agreements
CP Knowledge Centre
CP Consulting

Updated report

Provides comprehensive understanding and unprecedented access to the  biomarker partnering agreements deals and agreements entered into by the worlds leading healthcare companies. More

 

Featured partnering deals

Merck and Newlink ink Ebola vaccine deal

November 25, 2014 : big pharma, Merck, partnering, vaccine

Merck and NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate more »

BMS and Five Prime partner on Opdivo – FPA008 combination

November 25, 2014 : big pharma, Bristol-Myers Squibb, partnering

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008 more »

 More partnering deals | all deals at Deal Monitor


Featured M&A deals

BioMarin acquires Prosensa for up to $840 million

November 25, 2014 : acquisition, big biotech, M&A

BioMarin Pharmaceutical and Prosensa Holding have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million more »

Actavis agrees to acquire Allergan in $66 billion deal

November 18, 2014 : acquisition, Actavis, Allergan, big pharma, M&A

Actavis and Allergan have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock more »

 More M&A deals | all deals at Deal Monitor

Featured financing deals

Second Sight secures $32 million IPO

November 24, 2014 : financing, ipo, medical device

Second Sight Medical Products secured it pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share more »

Galena receives $55 million from Lincoln Park

November 22, 2014 : biotech, financing, pharma partnering

Galena Biopharma announced the execution of a purchase agreement for up to $55.0 million with Lincoln Park Capital Fund more »

 More financing deals | all deals at Deal Monitor

Latest Dealtalk

Bayer hungry for pharma deals to expand business

October 31, 2014 : Bayer, big pharma, dealtalk, pharma deals

Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets  that it is looking for further takeover pharma deals.  more »

Equity firms eye Bayer’s plastic business merger

October 27, 2014 : Bayer, big pharma, business merger

Private equity firms are circling Bayer’s €10bn plastics business merger, hoping to divert the German drugmaker from its plan to list the division, two people familiar with the matter said yesterday. more »

 More dealtalk

Featured reports

Personalized Medicine Partnering Terms and Agreements

Publication date: November 2014

Companion Diagnostics Partnering Terms and Agreements

Publication date: November 2014

Pharmacogenomics Partnering Terms and Agreements

Publication date: November 2014

Option and Evaluation Partnering Terms and Agreements

Publication date: November 2014

Top 50 Big Pharma Partnering and M&A

Publication date: October 2014

Global Joint Venture Partnerships

Publication date: October 2014

Bioinformatics Partnering Terms and Agreements

Publication date: October 2014

Top 50 Big Biotech Partnering and M&A

Publication date: October 2014

Molecular Diagnostics Partnering Terms and Agreements

Publication date: October 2014

Regenerative Medicine Partnering Terms and Agreements

Publication date: October 2014

NEW: Therapy deal reports covering all major indications

Including partnering in oncology, cardiovascular, CNS, metabolic, dermatology, dental, infectives, immunologypsychiatry, genitourinary.....plus many others

View all reports

Scorecard

Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.

Available scorecards:

Partnering

M&A

Financing

Top 50 pharma partnering

Top 50 biotech partnering

Top pharma R&D spend

Deal metrics - by stage of development, therapy area, industry sector

Print Friendly
cabannerad300x150new4gif
RSS Feed Linked In Twitter

Latest Tweets

cpbannerad300x150new3gif
biotech-china-300x150jpg
fdagif